Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings (STIMIC)

15 juni 2026 uppdaterad av: Romina Pena, Hospital Clinic of Barcelona

The STIMIC Trial: A Multicenter Randomized Control Trial Evaluating the Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings

BACKGROUND Loop ileostomies are a type of stoma frequently used to protect high-risk colorectal anastomoses (surgical reconnection of the intestines), for example following rectal cancer resection. Temporary diversion of intestinal transit does not reduce the risk of anastomotic failure, but it does lower the morbidity and mortality associated with potential pelvic sepsis. Unfortunately, a second surgical procedure is required to restore intestinal continuity, and this carries its own risk of complications, the most common being postoperative ileus (temporary paralysis of bowel motility associated with abdominal distension, absence of bowel movements, nausea, and vomiting), which occurs in up to 20% of cases.

Several strategies have been proposed to reduce this problem, including stimulation of the efferent limb of the ileostomy (the part that is connected to the unused colon). This intervention consists of instilling a substance through the efferent limb of the ileostomy into the colon, simulating natural intestinal transit. It emerged as a harmless alternative aimed at reversing changes in the excluded colon in preparation for restoration of intestinal continuity. Several Spanish studies have investigated this technique, concluding that it is safe and significantly reduces the rate of postoperative ileus, thereby shortening hospital stay. Regarding the mechanism by which this intervention may be effective, there are studies investigating the changes that occur during diversion of intestinal transit:

  1. Histopathology: reduced muscular contractility and the presence of intestinal villi in the efferent intestinal limb and excluded colon, which improve once intestinal flow is restored.
  2. Microbiome: significant loss of microbiota in the defunctionalized colon, which progressively recovers with natural intestinal transit and reintroduction of a fiber-rich diet.

Structural and microbiota-related changes favor the development of diversion colitis, a condition associated with erratic bowel habits once intestinal transit is restored. In an attempt to reverse this condition, several products have been tested for stimulation of the efferent limb of the ileostomy: probiotics, short chain fatty acids, saline solution with a thickening agent, and the patient's own intestinal contents, a well-tolerated and effective technique, in some cases superior to saline-based alternatives.

Overall, the available evidence is of low quality due to the limited number of patients studied and protocol variability. For this reason, we propose the implementation of a protocol for stimulation of the distal ileostomy limb prior to ileostomy closure, either with saline solution and thickening agent (the most widely described technique in the literature) or physiological stimulation using the patient's own intestinal contents.

The protocol consists of several sessions in which the instilled volume is progressively increased. This intervention will be performed on an outpatient basis, once daily, during the two weeks prior to surgery.

This process promotes the onset of bowel movements through the anus, which progressively become more formed and less frequent, approaching a more normal bowel habit. Only minor adverse effects have been described with this technique, including cramp-like abdominal pain in 27.6% of sessions. Recently, a nationwide study confirmed the favorable clinical outcomes following distal ileostomy limb stimulation before ileostomy closure. However, to our knowledge, no studies have evaluated its effect on intestinal microbiota.

HYPOTHESIS Distal limb stimulation of the ileostomy before its closure helps in the recovery of the colorectal microbiome and tissue. This associates with lower postoperative complications, specially postoperative ileus.

OBJECTIVES To gain knowledge regarding changes in intestinal microbiota composition before and after stimulation, in order to better understand recovery of intestinal function following this procedure. We will also analyze outcomes after ileostomy closure following efferent limb stimulation, determining the incidence of postoperative complications, particularly postoperative ileus.

METHODOLOGY

Patients will be randomly assigned to one of three groups:

  1. Control (no intervention other than the usual preoperative protocol)
  2. Stimulation with serum and thickener
  3. Stimulation with own stoma output

Samples will be collected in all patients:

  1. Stoma output
  2. Stool, before stimulation, if performed
  3. Stool, after stimulation, if performed
  4. Stool, a month after surgery

For a group of patients, the ones recruited at Hospital Clínic, rectal biopsies will also be collected before and after stimulation, to compare the effect of the treatment in the colonic tissue. We will collect clinical data during the whole process regarding postoperative complications.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Interventionell

Inskrivning (Beräknad)

90

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Romina Pena, MD
  • Telefonnummer: +34 617333153
  • E-post: PENA@clinic.cat

Studera Kontakt Backup

  • Namn: Miguel Pera, MD, PhD
  • Telefonnummer: 5559 +34 932275400
  • E-post: PERA@clinic.cat

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion criteria:

  1. Patients 18 yo and older, with a loop ileostomy after colorectal surgery for malignant or benign disease and a barium enema that rules out colorectal anastomotic leak or stenosis.
  2. Patients must be self-sufficient in their stoma care or dispose of assistance by a family member or healthcare provider.
  3. Patients must reside no further than 50km from the hospital and dispose of postoperative home-assistance by a family member or healthcare provider.

Exclusion criteria:

  1. Patients with a terminal ileostomy or a closed distal limb, inaccesible to preoperative stimulation.
  2. Patients with the diagnosis of inflammatory bowel disease.
  3. Patients incapable of comprehending or signing the informed consent.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Control
No efferent limb stimulation.
Aktiv komparator: Serum stimulation
Efferent limb stimulation with serum and thickener.
The intervention has been described in previous studies, but the investigation of the microbiome changes associated with the obtained clinical results hasn't been described to date. Also, a study with three arms hasn't been published to date.
Andra namn:
  • efferent limb stimulation
  • physiological stimulation
Aktiv komparator: Physiological stimulation
Efferent limb stimulation with the patient's own stoma output.
The intervention has been described in previous studies, but the investigation of the microbiome changes associated with the obtained clinical results hasn't been described to date. Also, a study with three arms hasn't been published to date.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in colorectal microbiome before and after efferent limb stimulation prior to stoma closure.
Tidsram: From enrollment to the end of follow-up at 3 months.
Descriptive analysis of the microbiome profiles of the three groups of patients (control, stimulation with serum, stimulation with own stoma output).
From enrollment to the end of follow-up at 3 months.
Changes in colorectal tissue before and after efferent limb stimulation prior to stoma closure.
Tidsram: From the time of first biopsy (before stimulation) to the second one (surgery day).
Description of the tissue obtained by biopsy of the rectum, before and after stimulation of the ileostomy.
From the time of first biopsy (before stimulation) to the second one (surgery day).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Postoperative complications after stoma closure.
Tidsram: From the surgery (ileostomy closure) to 30 days follow-up.
Incidence of postoperative ileus and surgical site infection.
From the surgery (ileostomy closure) to 30 days follow-up.
Functional outcomes after efferent limb stimulation (LARS score)
Tidsram: From enrollment to the end of follow-up a 3 months.

Description of the funcional (defecatory) outcomes after ileostomy closure.

LARS (Low Anterior Resection Syndrome) score: total score ranges from 0-42 points (0-20 is equivalent no LARS, 21-29 points to minor LARS, and 30-42 to major LARS).

From enrollment to the end of follow-up a 3 months.
Functional outcomes after efferent limb stimulation (Vaizey score)
Tidsram: From enrollment to the end of follow-up at 3 months.

Description of the funcional (defecatory) outcomes after ileostomy closure.

Vaizey score (also known as the St. Mark's Incontinence Score): total score ranges from 0 (perfect continence) to 24 points (severe incontinence).

From enrollment to the end of follow-up at 3 months.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Romina Pena, MD, Hospital Clinic of Barcelona

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2026

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 mars 2028

Studieregistreringsdatum

Först inskickad

26 maj 2026

Först inskickad som uppfyllde QC-kriterierna

8 juni 2026

Första postat (Faktisk)

10 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • HCB/2026/0615

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All IPD that underlie results in a publication.

Tidsram för IPD-delning

Beginning 1 month and ending 1 year after the publication of results.

Kriterier för IPD Sharing Access

IPD and supporting information of this study might be accessed by fellow researchers with a future study, related to our published findings. Researchers must submit a request for data sharing by contacting the principal investigator, who will also be the corresponding author in the future published data. The request to access IPD will be reviewed by the principal investigator (Romina Pena).

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera